PDX

Oncomatryx acquires Tube Pharmaceuticals GmbH to consolidate its pioneering pipeline of ADCs targeting the tumor microenvironment

Retrieved on: 
星期四, 五月 18, 2023
Professional Services, Oncology, Health, Venture Capital, Pharmaceutical, Biotechnology, National Center of Oncology (Azerbaijan), Rat, University of Stuttgart, University, PDX, Cytolysin, Harvard University, Syngenic, Tumor microenvironment, Chemistry, Hospital, Laboratory, MD Anderson Cancer Center, FIH, ADC, Spacecraft, Fibroblast, Pharmaceutical industry, Oncomatryx

The multimillion €uros transaction is a strategic decision by Oncomatryx that will foster its leadership in the field of ADCs targeting the tumor microenvironment.

Key Points: 
  • The multimillion €uros transaction is a strategic decision by Oncomatryx that will foster its leadership in the field of ADCs targeting the tumor microenvironment.
  • It culminates a decade-long alliance between Oncomatryx and Tube that has already rendered clinical-stage ADCs targeting the Tumor Microenvironment.
  • Oncomatryx's pioneering drug OMTX705, which incorporates the cytolysin toxic payload developed by Tube, is a first-in-class antibody-drug conjugate targeting cancer-associated fibroblasts.
  • Oncomatryx now owns the comprehensive portfolio of cytolysins synthesized by Tube and the cutting-edge technology developed in its laboratories.

Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期四, 五月 11, 2023
CLL, TNBC, AACR, Liver disease, ASH, Therapy, CRC, HER2, PALO, Venetoclax, Survival, Cancer, G&A, Research, SMDC, Pharma, BTK, Lung, Acute myeloid leukemia, AML, Azacitidine, Patient, Annual general meeting, ADC, CRS, Neoplasm, Spacecraft, R, IND, Tumor microenvironment, Society, Safety, Pharmaceutical industry, Medical imaging, Vaccine, Cryptocurrency, PDX

PALO ALTO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • “The ADC space is going through an exciting period of innovation,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx.
  • At AACR 2023, Vincerx presented preclinical data on the synthesis and characterization of novel SMDCs with different payloads.
  • For the first quarter ended March 31, 2023, Vincerx reported a net loss of approximately $14.3 million, or $0.68 per share.
  • For the first quarter ended March 31, 2022, Vincerx reported a net loss of approximately $16.4 million, or $0.79 per share.

Sapience Therapeutics Awarded $2 Million Grant to Evaluate the Therapeutic Potential of ST316, a First-in-Class β-catenin Antagonist

Retrieved on: 
星期四, 五月 4, 2023
AACR, BCL9, PD, Therapy, TIL, SBIR, Neoplasm, Clinical trial, Cancer, American Association for Cancer Research, Biomarker, Wisdom, WNT, Bangladesh Technical Education Board, Trial of the century, PDX, National Cancer Institute, Patient, Small Business Innovation Research, TME, PD-1, FDA, NCI, Pharmacology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tumor microenvironment, SVP, NIH, Food, Pharmaceutical industry

The proposed non-clinical studies will investigate pharmacodynamic biomarkers for ST316, a first-in-class β-catenin antagonist, and evaluate the impact of ST316 on the tumor microenvironment (TME) in patient-derived cancer models.

Key Points: 
  • The proposed non-clinical studies will investigate pharmacodynamic biomarkers for ST316, a first-in-class β-catenin antagonist, and evaluate the impact of ST316 on the tumor microenvironment (TME) in patient-derived cancer models.
  • "ST316 has tremendous therapeutic promise, with a robust preclinical data package that includes a favorable safety profile and significant anti-tumor activity.
  • In addition, at the American Association for Cancer Research (AACR) Annual Meeting 2023, Sapience presented late-breaking data on ST316 highlighting its immunotherapeutic potential.
  • This grant was supported by the National Cancer Institute of the National Institutes of Health under Award Number 2R44CA265503-02A1.

LIfT BioSciences announces data demonstrating potent killing of pancreatic cancer tumouroids

Retrieved on: 
星期四, 五月 4, 2023
PDAC, Pancreatic cancer, ICIS, Neutrophil, Survival, Paclitaxel, Hope, Immunity, Cancer, Research, Lift, TILS, Neoplasm, Patient, Immune system, TME, Cell, Biology, Hirschhorn, Cisplatin, Pembrolizumab, Vaccine, Pharmaceutical industry, Medical imaging, PDX

- IMAN is the world’s first neutrophil-based cell therapy, generated from the haematopoietic stem cells of donors with exceptional anti-cancer innate immunity

Key Points: 
  • - IMAN is the world’s first neutrophil-based cell therapy, generated from the haematopoietic stem cells of donors with exceptional anti-cancer innate immunity
    London, 4 May 2023 ­– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging leading biotech in neutrophil biology bringing to market a first-in-class allogeneic innate cell therapy, today announces preclinical data demonstrating that its Immunomodulatory Alpha Neutrophil product (IMAN) showed potent killing of pancreatic cancer tumouroids.
  • Immune Checkpoint Inhibitors (ICIs) may help a small proportion of patients, but ultimately, chances of survival are less than 5%.
  • In the tumouroid model, a similar outcome was observed with paclitaxel having no cancer cell killing effect, whilst a single dose of gemcitabine resulted in destruction of the tumoroid.
  • This new direct killing data builds on previous data announced by LIfT using PDAC biopsies demonstrating that IMANs modify the Tumour Micro-Environment (TME) and then activate patients own immune cells into attack mode, such as Tumour Infiltrating Lymphocytes (TILs).

LIfT BioSciences announces data demonstrating potent killing of pancreatic cancer tumouroids

Retrieved on: 
星期四, 五月 4, 2023
PDAC, Pancreatic cancer, ICIS, Neutrophil, Survival, Paclitaxel, Hope, Immunity, Cancer, Research, Lift, TILS, Neoplasm, Patient, Immune system, TME, Cell, Biology, Hirschhorn, Cisplatin, Pembrolizumab, Vaccine, Pharmaceutical industry, Medical imaging, PDX

- IMAN is the world’s first neutrophil-based cell therapy, generated from the haematopoietic stem cells of donors with exceptional anti-cancer innate immunity

Key Points: 
  • - IMAN is the world’s first neutrophil-based cell therapy, generated from the haematopoietic stem cells of donors with exceptional anti-cancer innate immunity
    London, 4 May 2023 ­– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging leading biotech in neutrophil biology bringing to market a first-in-class allogeneic innate cell therapy, today announces preclinical data demonstrating that its Immunomodulatory Alpha Neutrophil product (IMAN) showed potent killing of pancreatic cancer tumouroids.
  • Immune Checkpoint Inhibitors (ICIs) may help a small proportion of patients, but ultimately, chances of survival are less than 5%.
  • In the tumouroid model, a similar outcome was observed with paclitaxel having no cancer cell killing effect, whilst a single dose of gemcitabine resulted in destruction of the tumoroid.
  • This new direct killing data builds on previous data announced by LIfT using PDAC biopsies demonstrating that IMANs modify the Tumour Micro-Environment (TME) and then activate patients own immune cells into attack mode, such as Tumour Infiltrating Lymphocytes (TILs).

NICO Awards $180,000 Grant to Study GBM Progression Using Novel Longitudinal Serial Sampling in Translational Research

Retrieved on: 
星期三, 四月 19, 2023
Human, GBM, APS, Medical school, IIS, Research, Brain, Doctor of Philosophy, Glioblastoma, PDX, DSM-IV codes, Acquisition, NICO, Medical University of South Carolina, HIV disease progression rates, Patient, Physician, MUSC, Growth, Neoplasm, Neuro, Pharmaceutical industry, Medical imaging

INDIANAPOLIS, April 19, 2023 /PRNewswire/ -- NICO Corporation has awarded Arabinda Das, PhD, neuroscientist and neuro-oncology assistant professor at the Medical University of South Carolina (MUSC), a $180,000 Investigator Initiated Study (IIS) grant supporting the development of a new glioblastoma (GBM) patient-derived xenograft (PDX) model. The study uses the new NICO Myriad® Research Laboratory System to safely and progressively sample intracranial tissue over time in murine models without the need for euthanization. This is the first study involving fresh human tumor tissue collected intraoperatively and implanted for serial sampling in translational research.

Key Points: 
  • This is the first study involving fresh human tumor tissue collected intraoperatively and implanted for serial sampling in translational research.
  • First study to use fresh human tumor tissue collected in OR & implanted for serial sampling in research host over time.
  • The goal of the study is to evaluate the impact of various interventions on GBM cellular, genetic and microenvironment information over tumor progression through longitudinal serial biopsy – assessing the tumor and disease state progression in the same murine model over time.
  • The NICO IIS grant program is dedicated to supporting novel pre-clinical and clinical research efforts related to improved patient and economic outcomes using NICO technologies.

Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
星期三, 四月 19, 2023
CLL, Lymphoma, AACR, ASH, Therapy, KSP, Doctor of Philosophy, Chronic lymphocytic leukemia, Follicular lymphoma, Lymphoid leukemia, DLBCL, Neoplasm, PALO, Survival, Cancer, Toxicity, Antibody, B-cell lymphoma, PDX, Plasma, Patient, Mantle cell lymphoma, CXCR5, Mouse, Immunohistochemistry, ADC, MCL, Poster, IND, Human, Safety, Pharmaceutical industry, Vaccine, Medical imaging

PALO ALTO, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented a poster of VIP924 preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • PALO ALTO, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented a poster of VIP924 preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
  • This modification allows for intracellular accumulation of VIP716 in CXCR5+ tumor cells, providing greater efficacy, and prevents cellular penetration into healthy tissues, reducing toxicity.
  • “We are thrilled to continue advancing our bioconjugation platform with our newest ADC, VIP924,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx.
  • “At AACR, VIP924 showed meaningful preclinical activity in a panel of lymphoma cell lines and in cell line-derived and patient-derived lymphoma mouse models.

Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023

Retrieved on: 
星期一, 四月 17, 2023
Carcinoma, MYC, Index, AACR, PD, DLBCL, Survival, Disclosure, Clinical trial, Cancer, Lung cancer, American Association for Cancer Research, NSCLC, Treatment of lung cancer, SCLC, Patient, MTD, Growth, Trial of the century, AI, Therapy, Horizon, CDK9, GSPT1, MGD, Safety, Medical imaging, Pharmaceutical industry, Fine chemical, PDX

The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL.

Key Points: 
  • The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL.
  • “Our extensive preclinical work on MRT-2359 forms a strong basis for our ongoing clinical trial by providing insight into the effects of GSPT1 degradation on the MYC pathway in cancer.
  • We look forward to reporting initial data from the Phase 1 arm of the trial later this year,” said Owen Wallace, Ph.D., Chief Scientific Officer of Monte Rosa.
  • The preclinical data were presented as follows:
    Title: New Drugs on the Horizon - Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers
    Session: New Drugs on the Horizon: Part 3
    Title: Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction

Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
星期一, 四月 17, 2023
Tissue, TNBC, DNA, AACR, Liver disease, Cell death, Therapy, CRC, Phosphorylation, CPT, HER2, PALO, Cancer, Traffic barrier, NSCLC, SMDC, Integrin, Lung, Colon, Protein, DNA repair, Partial, Patient, NE, Mouse Models of Human Cancer database, Irinotecan, TME, CRS, ADC, Neoplasm, Poster, Tumor microenvironment, Camptothecin, Breast cancer, Vaccine, Medical imaging, PDX

VIP236 is a first-in-class SMDC with a tailored design to efficiently treat patients with aggressive and metastatic cancer.

Key Points: 
  • VIP236 is a first-in-class SMDC with a tailored design to efficiently treat patients with aggressive and metastatic cancer.
  • VIP236 binds to activated αVβ3 integrin, allowing specific homing to the tumor, and is efficiently cleaved by neutrophil elastase (NE).
  • Both proteins are present in the tumor microenvironment (TME), are highly expressed in advanced metastatic tumors, and are associated with poor prognosis.
  • Anticancer activity occurs after a specific and targeted release of an optimized CPT payload by NE in the TME.

Biotheryx Presents Preclinical CDK4/6 and SOS1 Protein Degrader Data at AACR 2023 Annual Meeting

Retrieved on: 
星期一, 四月 17, 2023
Immortalised cell line, KRAS, AACR, CDK6, Inflammation, Neoplasm, CDK, SOS1, Cancer, Cell proliferation, PRB, American Association for Cancer Research, Publication, PDX, Drug resistance, Patient, SAN, Annual general meeting, PDF, GEF, Pancreatic tumor, Breast cancer, Pharmaceutical industry, Vaccine, MCF7, CDK4, IND

SAN DIEGO, April 17, 2023 /PRNewswire/ -- Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory disease, today announced data presentations on two first-in-class programs at the American Association for Cancer Research (AACR) 2023 Annual Meeting held in Orlando, Florida, on April 14–19, 2023. The presentations highlight preclinical data for bifunctional degraders of cyclin-dependent kinase (CDK) 4/6 for the treatment of solid tumors, and bifunctional degraders of son of sevenless homolog 1 (SOS1) for the treatment of KRAS mutant cancers. Additionally, the Company has nominated BTX-9341 as a development candidate for the CDK4/6 degrader program and has commenced IND-enabling studies.

Key Points: 
  • Additionally, the Company has nominated BTX-9341 as a development candidate for the CDK4/6 degrader program and has commenced IND-enabling studies.
  • "At AACR, we are proud to share encouraging preclinical data that highlights the potential of these exciting programs.
  • Similarly, in preclinical KRAS mutant cancer models, our SOS1 degraders resulted in greater than 90% degradation of SOS1 in tumors and led to significant tumor growth inhibition."
  • These data support the potential of SOS1 degradation as a valuable treatment option for a range of KRAS mutant cancers.